
  
    
      
        Introduction_NNP
        Appropriate_NNP clinical_JJ treatment_NN of_IN an_DT individual_NN with_IN
        multiple_JJ adjacent_JJ breast_NN tumors_NNS can_MD be_VB difficult_JJ to_TO
        determine_VB ._. If_IN the_DT tumors_NNS originated_VBN from_IN the_DT same_JJ clone_NN ,_,
        then_RB they_PRP are_VBP likely_JJ to_TO have_VB common_JJ genetic_JJ changes_NNS and_CC
        behave_VB in_IN a_DT similar_JJ manner_NN ._. Alternatively_RB ,_, if_IN the_DT tumors_NNS
        are_VBP separate_JJ primary_JJ lesions_NNS ,_, then_RB different_JJ genetic_JJ
        pathways_NNS might_MD have_VB been_VBN disrupted_VBN and_CC the_DT tumors_NNS may_MD
        require_VB separate_JJ treatment_NN strategies_NNS [_NN 1_CD ]_NN ._. Current_JJ methods_NNS
        to_TO detect_VB tumor_NN clonality_NN include_VBP methylation-sensitive_JJ
        restriction_NN enzyme_NN digestions_NNS and_CC detection_NN of_IN X_NNP chromosome_NN
        polymorphisms_NNS ,_, neither_DT of_IN which_WDT give_VBP an_DT overall_JJ genomic_JJ
        assessment_NN of_IN tumors_NNS [_NN 2_CD ]_NN ._.
        We_PRP tested_VBD the_DT capabilities_NNS of_IN oligonucleotide_NN
        microarrays_NNS in_IN determining_VBG tumor_NN clonality_NN ._. We_PRP obtained_VBD
        samples_NNS from_IN adjacent_JJ tumors_NNS from_IN a_DT single_JJ individual_NN ,_, and_CC
        compared_VBD the_DT transcriptional_NN profile_NN of_IN each_DT tumor_NN ._. For_IN
        comparison_NN ,_, we_PRP determined_VBD the_DT gene_NN expression_NN profiles_NNS of_IN
        tumors_NNS with_IN similar_JJ clinical_JJ characteristics_NNS from_IN five_CD
        different_JJ individuals_NNS ._. These_DT findings_NNS were_VBD interpreted_VBN in_IN
        the_DT context_NN of_IN the_DT observed_VBN chip-to-chip_JJ variation_NN and_CC with_IN
        duplicate_VB labeling_VBG of_IN the_DT same_JJ RNA_NNP source_NN ._.
      
      
        Patients_NNS and_CC method_NN
        
          Study_NN subjects_NNS and_CC selection_NN criteria_NNS
          Two_CD foci_NN of_IN IDC_NNP were_VBD removed_VBN from_IN the_DT right_JJ breast_NN of_IN
          an_DT 87_CD -_: year-old_JJ woman_NN (_( tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP )_) ._. Neither_DT
          mam-mography_JJ ,_, intraoperative_JJ palpation_NN ,_, nor_CC histologic_JJ
          analysis_NN revealed_VBD a_DT physical_JJ connection_NN between_IN these_DT
          tumors_NNS ._. Five_CD tumors_NNS from_IN separate_JJ individuals_NNS with_IN the_DT
          same_JJ clinical_JJ characteristics_NNS were_VBD also_RB selected_VBN as_IN
          comparisons_NNS (_( Table_NNP 1_CD ,_, and_CC Supplementary_NNP Table_NNP 1_LS )_) ._.
        
        
          RNA_NNP sample_NN preparation_NN
          Total_NNP RNA_NNP was_VBD extracted_VBN from_IN dissected_VBN tumor_NN
          containing_VBG 90_CD %_NN or_CC greater_JJR IDC_NNP using_VBG TRIzol_NNP ®_NN (_( Life_NNP
          Technologies_NNPS ,_, Grand_NNP Island_NNP ,_, NY_NNP ,_, USA_NNP )_) followed_VBN by_IN RNeasy_NNP
          ®_NN (_( Qiagen_NNP ,_, Valencia_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Total_NNP RNA_NNP (_( 20_CD μg_NN )_) was_VBD used_VBN
          to_TO synthesize_VB double-stranded_JJ cDNA_NN using_VBG Superscript_NNP
          ®_NN Choice_NNP System_NNP (_( Life_NNP Technologies_NNPS )_) ,_, and_CC the_DT template_NN for_IN
          an_DT 
          in_IN vitro_NN transcription_NN reaction_NN was_VBD
          used_VBN to_TO synthesize_VB biotin-labeled_JJ antisense_NN cRNA_NN
          (_( BioArray_NNP ™_NN High_NNP Yield_NNP RNA_NNP Transcript_NNP Labeling_VBG Kit_NNP ;_: Enzo_NNP
          Diagnostics_NNPS ,_, Farmingdale_NNP ,_, NY_NNP ,_, USA_NNP )_) ._. Labeled_NNP cRNA_NN was_VBD
          fragmented_JJ ,_, hybridized_JJ ,_, and_CC scanned_JJ as_IN described_VBN in_IN the_DT
          Affymetrix_NNP GeneChip_NNP ®_NN protocol_NN (_( Affymetrix_NNP ,_, Inc_NNP )_) ._.
          Affymetrix_NNP U_NNP 95_CD A_DT arrays_NNS contain_VBP 12_CD ,_, 500_CD known_VBN human_JJ genes_NNS
          (_( see_VB Lipshutz_NNP 
          et_CC al_NN [_NN 3_CD ]_NN )_) ._.
        
        
          Data_NNP analysis_NN
          Expression_NNP profiles_NNS were_VBD analyzed_VBN using_VBG GeneChip_NNP
          ®_NN Analysis_NNP Suite_NNP 3_CD ._. 3_CD (_( Affymetrix_NNP ,_, Inc_NNP )_) ._. Only_RB relative_JJ
          changes_NNS equal_JJ to_TO or_CC greater_JJR than_IN twofold_NN level_NN of_IN gene_NN
          expression_NN were_VBD considered_VBN ._. The_DT average_JJ difference_NN values_NNS
          obtained_VBN for_IN each_DT tumor_NN were_VBD plotted_VBD in_IN log_NN scale_NN on_IN
          scatter_NN graphs_NNS using_VBG GeneChip_NNP ®_NN ._. The_DT average_JJ difference_NN
          values_NNS were_VBD exported_VBN into_IN JMPIN_NNP ®_NN 3_CD ._. 2_LS ._. 6_CD (_( SAS_NNP Institute_NNP ,_,
          Inc_NNP )_) ._. Then_RB ,_, all_DT 12_CD ,_, 500_CD data_NNS points_NNS were_VBD used_VBN to_TO generate_VB
          a_DT pairwise_NN (_( Pearson_NNP 's_POS )_) correlation_NN and_CC ,_, after_IN sorting_VBG the_DT
          average_JJ difference_NN values_NNS by_IN magnitude_NN ,_, a_DT ranked_VBD
          (_( Spearman_NNP 's_POS )_) correlation_NN coefficient_NN for_IN each_DT set_NN of_IN
          sample_NN comparisons_NNS was_VBD calculated_VBN [_NN 4_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Chip-to-chip_NNP variation_NN
          In_IN order_NN to_TO measure_VB the_DT variation_NN in_IN gene_NN expression_NN
          between_IN individual_JJ Affymetrix_NNP oligonucleotide_NN arrays_NNS ,_, the_DT
          labeled_VBN cRNA_NN target_NN prepared_VBN from_IN tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP were_VBD
          each_DT hybridized_JJ to_TO two_CD different_JJ U_NNP 95_CD A_DT chips_NNS ._. For_IN each_DT
          cRNA_NN sample_NN ,_, approximately_RB 50_CD %_NN of_IN the_DT 12_CD ,_, 500_CD transcripts_NNS
          represented_VBD on_IN the_DT chip_NN were_VBD considered_VBN '_POS present_JJ '_POS using_VBG
          Affymetrix_NNP algorithms_NNS ._.
          The_DT data_NNS from_IN the_DT 5_CD A_DT duplicate_VB experiments_NNS (_( 5_CD A_DT and_CC
          5_CD ADUP_NNP )_) had_VBD a_DT pairwise_NN correlation_NN coefficient_NN of_IN 0_CD ._. 995_CD
          (_( Fig_NNP ._. 1_LS )_) ._. Fifty_NNP genes_NNS showed_VBD a_DT twofold_NN or_CC greater_JJR
          difference_NN in_IN expression_NN between_IN duplicate_VB data_NNS sets_NNS ._.
          Likewise_RB ,_, the_DT 5_CD B_NNP duplicate_VB experiments_NNS (_( 5_CD B_NNP and_CC 5_CD BDUP_NNP )_) had_VBD
          a_DT pairwise_NN correlation_NN coefficient_NN of_IN 0_CD ._. 995_CD ,_, with_IN 36_CD
          genes_NNS showing_VBG a_DT twofold_NN or_CC greater_JJR difference_NN in_IN
          expression_NN (_( Table_NNP 2_LS )_) ._. None_NN of_IN the_DT 36_CD genes_NNS that_WDT were_VBD
          differentially_RB expressed_VBN in_IN the_DT 5_CD B_NNP /_NN 5_CD BDUP_NNP experiment_NN were_VBD
          also_RB differentially_RB expressed_VBD in_IN the_DT 5_CD A_DT /_NN 5_CD ADUP_NNP experiment_NN ,_,
          suggesting_VBG that_IN these_DT changes_NNS represent_VBP random_JJ
          experimental_JJ variation_NN ._.
        
        
          Variables_NNP in_IN sample_NN preparation_NN
          In_IN order_NN to_TO measure_VB the_DT variation_NN in_IN gene_NN expression_NN
          seen_VBN when_WRB different_JJ cRNA_NN targets_NNS are_VBP prepared_VBN from_IN the_DT
          same_JJ total_JJ RNA_NNP source_NN and_CC hybridized_JJ to_TO separate_VB U_NNP 95_CD A_DT
          chips_NNS ,_, total_JJ RNA_NNP from_IN tumor_NN 5_CD A_DT was_VBD used_VBN to_TO prepare_VB cRNA_NN
          three_CD weeks_NNS after_IN the_DT initial_JJ preparation_NN (_( 5_CD AsRNA_NNP )_) ._. Gene_NNP
          expression_NN patterns_NNS from_IN 5_CD A_DT and_CC 5_CD AsRNA_NNP had_VBD a_DT pairwise_NN
          correlation_NN coefficient_NN of_IN 0_CD ._. 915_CD ,_, with_IN 165_CD genes_NNS having_VBG a_DT
          twofold_NN or_CC greater_JJR difference_NN in_IN expression_NN (_( Table_NNP 2_LS )_) ._.
          Four_CD genes_NNS from_IN the_DT 5_CD A_DT /_NN 5_CD ADUP_NNP experiment_NN were_VBD also_RB
          differentially_RB expressed_VBD at_IN twofold_NN or_CC greater_JJR levels_NNS in_IN
          the_DT comparison_NN of_IN 5_CD A_DT with_IN 5_CD AsRNA_NNP ._. Thus_RB ,_, use_NN of_IN the_DT same_JJ
          RNA_NNP source_NN resulted_VBD in_IN the_DT additional_JJ perturbation_NN of_IN
          approximately_RB 100_CD genes_NNS over_IN the_DT observed_VBN chip-to-chip_JJ
          variation_NN ,_, again_RB most_RBS likely_JJ representing_VBG primarily_RB
          random_JJ experimental_JJ variation_NN ._.
        
        
          Comparison_NNP of_IN adjacent_JJ tumor_NN gene_NN expression_NN
          The_DT gene_NN expression_NN profiles_NNS from_IN tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP had_VBD
          a_DT pairwise_NN correlation_NN of_IN 0_CD ._. 987_CD ,_, with_IN 149_CD genes_NNS having_VBG a_DT
          twofold_NN or_CC greater_JJR difference_NN in_IN expression_NN (_( Table_NNP 2_LS )_) ._.
          When_WRB the_DT expression_NN profiles_NNS of_IN cRNA_NN targets_NNS from_IN all_DT
          duplicate_VB experiments_NNS were_VBD compared_VBN (_( Table_NNP 2_LS )_) ,_, the_DT
          observed_VBN pairwise_NN correlation_NN ranged_VBD from_IN 0_CD ._. 982_CD to_TO 0_CD ._. 987_CD ,_,
          with_IN 148_CD -_: 182_CD genes_NNS expressed_VBD with_IN twofold_NN or_CC greater_JJR
          differences_NNS ._. Thus_RB ,_, the_DT number_NN of_IN differentially_RB expressed_VBD
          genes_NNS observed_VBD when_WRB comparing_VBG cRNA_NN targets_NNS prepared_VBN from_IN
          tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP (_( 149_CD -_: 182_CD genes_NNS )_) was_VBD not_RB greater_JJR than_IN
          that_DT observed_VBD with_IN multiple_JJ sample_NN preparations_NNS from_IN the_DT
          same_JJ total_JJ RNA_NNP source_NN (_( 165_CD genes_NNS )_) ._. In_IN fact_NN ,_, the_DT pairwise_NN
          correlation_NN coefficient_NN of_IN the_DT adjacent_JJ tumors_NNS (_( 0_CD ._. 987_CD )_)
          was_VBD higher_JJR than_IN those_DT observed_VBN with_IN multiple_JJ cRNAs_NNS from_IN
          the_DT same_JJ total_JJ RNA_NNP source_NN (_( 0_CD ._. 915_CD )_) ._. Therefore_RB ,_, we_PRP conclude_VBP
          that_IN the_DT gene_NN expression_NN profiles_NNS of_IN tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP are_VBP
          so_RB similar_JJ that_IN they_PRP are_VBP indistinguishable_JJ by_IN the_DT
          oligonucleotide_NN microar-ray_JJ analysis_NN preformed_JJ here_RB ._.
          These_DT findings_NNS suggest_VBP that_IN tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP represent_VB
          multifocal_NN components_NNS of_IN the_DT same_JJ tumor_NN ,_, despite_IN a_DT lack_NN
          of_IN apparent_JJ physical_JJ contiguity_NN ._.
        
        
          Comparison_NNP of_IN tumors_NNS among_IN different_JJ
          individuals_NNS
          Tumors_NNP 5_CD A_DT and_CC 7_CD had_VBD a_DT pairwise_NN correlation_NN coefficient_NN
          of_IN 0_CD ._. 787_CD ,_, with_IN 1937_CD genes_NNS having_VBG a_DT twofold_NN or_CC greater_JJR
          difference_NN in_IN expression_NN (_( Table_NNP 2_LS )_) ._. Likewise_RB ,_, the_DT
          expression_NN profiles_NNS of_IN tumors_NNS 5_CD A_DT and_CC 9_CD generated_VBD a_DT
          pairwise_NN correlation_NN coefficient_NN of_IN 0_CD ._. 745_CD ,_, with_IN twofold_NN
          or_CC greater_JJR differences_NNS in_IN the_DT expression_NN of_IN 1764_CD genes_NNS
          (_( Table_NNP 2_LS )_) ._. As_IN expected_VBN from_IN the_DT pairwise_NN correlation_NN
          data_NNS ,_, the_DT expression_NN patterns_NNS based_VBN on_IN data_NNS from_IN the_DT 5_CD A_DT
          and_CC 5_CD ADUP_NNP experiments_NNS have_VBP a_DT closer_RBR linear_JJ relationship_NN
          on_IN the_DT scatter_NN plot_NN than_IN that_DT observed_VBD between_IN tumors_NNS 5_CD A_DT
          and_CC 9_CD ._. Interestingly_RB ,_, tumors_NNS 7_CD and_CC 9_CD differed_VBD by_IN only_RB
          1158_CD genes_NNS with_IN a_DT pairwise_NN correlation_NN coefficient_NN of_IN
          0_CD ._. 874_CD ,_, indicating_VBG that_IN these_DT tumors_NNS may_MD be_VB more_RBR similar_JJ
          to_TO each_DT other_JJ than_IN they_PRP are_VBP to_TO tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP ._.
          In_IN order_NN to_TO confirm_VB our_PRP$ results_NNS in_IN a_DT larger_JJR sample_NN
          set_VBD ,_, we_PRP preformed_JJ an_DT analysis_NN on_IN an_DT additional_JJ set_NN of_IN
          invasive_JJ breast_NN tumors_NNS from_IN different_JJ individuals_NNS (_( tumors_NNS
          3_CD ,_, 20_CD ,_, and_CC 32_CD )_) and_CC compared_VBD the_DT data_NNS with_IN those_DT from_IN
          tumor_NN 5_CD A_DT ,_, and_CC found_VBD similar_JJ correlation_NN coefficients_NNS to_TO
          those_DT seen_VBN with_IN tumors_NNS 7_CD and_CC 9_CD (_( Supplementary_NNP Table_NNP
          2_LS )_) ._.
        
        
          Ranked_NNP correlation_NN values_NNS of_IN samples_NNS
          Analysis_NNP of_IN the_DT distribution_NN of_IN the_DT average_JJ difference_NN
          values_NNS of_IN each_DT tumor_NN revealed_VBD a_DT skewed_VBN distribution_NN (_( data_NNS
          not_RB shown_VBN )_) ._. Therefore_RB ,_, a_DT nonparametric_JJ analysis_NN was_VBD used_VBN
          to_TO examine_VB the_DT complexity_NN of_IN the_DT data_NNS ._. Ranked_NNP correlation_NN
          coefficients_NNS were_VBD generated_VBN to_TO match_VB each_DT of_IN the_DT pairwise_NN
          correlation_NN coefficients_NNS calculated_VBN (_( Table_NNP 2_LS )_) ._. A_DT small_JJ
          drop_NN in_IN correlation_NN values_NNS (_( by_IN 0_CD ._. 027_CD -_: 0_CD ._. 035_CD )_) was_VBD observed_VBN
          in_IN the_DT ranked_VBN correlations_NNS compared_VBN with_IN the_DT pairwise_NN
          correlations_NNS in_IN the_DT duplicate_VB experiments_NNS and_CC those_DT that_WDT
          compared_VBD tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP (_( Table_NNP 2_LS )_) ._. Conversely_RB ,_, in_IN the_DT
          pairwise_NN data_NN sets_NNS with_IN lower_JJR correlation_NN coefficients_NNS
          (_( 5_CD A_DT /_NN 5_CD AsRNA_NNP ,_, 5_CD A_DT /_NN 7_CD i_NNP and_CC 5_CD A_DT /_NN 9_CD i_NNP )_) ,_, the_DT ranked_VBN correlation_NN
          calculations_NNS increased_VBD the_DT correlation_NN values_NNS by_IN
          0_CD ._. 021_CD -_: 0_CD ._. 098_CD ._. These_DT data_NNS suggest_VBP that_IN a_DT simple_JJ pairwise_NN
          correlation_NN comparison_NN may_MD not_RB fully_RB represent_VB the_DT
          relationship_NN between_IN gene_NN expression_NN profiles_NNS ._. Further_RB
          analyses_NNS of_IN these_DT data_NNS distributions_NNS and_CC algorithmic_JJ
          methods_NNS for_IN the_DT evaluation_NN of_IN background_NN and_CC systematic_JJ
          error_NN are_VBP currently_RB being_VBG conducted_VBN ._.
        
        
          Expression_NNP patterns_NNS for_IN selected_VBN genes_NNS of_IN known_VBN
          interest_NN in_IN breast_NN cancer_NN
          Differences_NNS in_IN gene_NN expression_NN for_IN specific_JJ genes_NNS that_WDT
          are_VBP implicated_VBN in_IN breast_NN carcinogenesis_NNS were_VBD examined_VBN ._. A_DT
          breast_NN cancer-associated_JJ gene_NN list_NN was_VBD derived_VBN by_IN
          querying_VBG the_DT Affymetrix_NNP EASI_NNP ®_NN Database_NNP U_NNP 95_CD A_DT ,_, with_IN
          '_POS breast_NN '_'' as_IN a_DT search_NN term_NN ._. A_DT total_NN of_IN 39_CD genes_NNS were_VBD
          identified_VBN from_IN this_DT search_NN ,_, but_CC only_RB 22_CD of_IN these_DT genes_NNS
          were_VBD judged_VBN present_JJ in_IN at_IN least_JJS one_CD tumor_NN (_( Table_NNP 3_LS )_) ._.
          Tumors_NNP 5_CD A_DT and_CC 5_CD B_NNP only_RB differed_VBD in_IN one_CD breast_NN cancer_NN
          related_VBD gene_NN ,_, the_DT human_JJ mammaglobin_NN β_NN precursor_NN gene_NN ,_, and_CC
          showed_VBD no_DT differences_NNS in_IN expression_NN for_IN the_DT remaining_VBG 22_CD
          genes_NNS examined_VBD ,_, including_VBG hormone_NN response_NN ,_, tumor_NN
          suppressor_NN and_CC mammary_JJ specific_JJ genes_NNS ._. The_DT human_JJ
          mammaglobin_NN protein_NN is_VBZ overexpressed_JJ in_IN a_DT variety_NN of_IN
          breast_NN carcinomas_NNS [_NN 5_CD ,_, 6_CD ]_NN ._. It_PRP does_VBZ not_RB appear_VB to_TO be_VB
          consistently_RB found_VBN in_IN a_DT specific_JJ subclass_NNS of_IN tumors_NNS ,_, or_CC
          is_VBZ its_PRP$ exact_JJ function_NN known_VBN ._. Tumor_NNP 5_CD A_DT had_VBD significantly_RB
          higher_JJR levels_NNS of_IN expression_NN of_IN the_DT vascular_NN endothelial_NN
          growth_NN factor_NN (_( 
          VEGF_NNP )_) gene_NN (_( 2_CD ._. 0_CD -_: fold_VB )_) ,_, the_DT breast_NN
          epithelial_NN antigen_NN (_( 
          BA_NNP 46_CD )_) gene_NN (_( 4_CD ._. 3_LS -_: fold_VB )_) and_CC the_DT
          human_JJ mammaglobin_NN gene_NN (_( 3_CD ._. 6_CD -_: fold_VB )_) ,_, as_IN compared_VBN with_IN tumor_NN
          7_CD ._.
          Tumor_NNP 5_CD A_DT had_VBD a_DT higher_JJR level_NN of_IN estrogen_NN receptor_NN (_( 
          ER_NNP )_) expression_NN than_IN did_VBD tumor_NN 7_CD
          (_( 12_CD ._. 7_CD -_: fold_VB )_) ,_, 
          BARD-_NNP 1_CD (_( 2_CD ._. 9_CD -_: fold_VB )_) ,_, and_CC thymidylate_NN
          synthetase_NN (_( 3_CD ._. 0_CD -_: fold_VB )_) ._. Tumor_NNP 5_CD A_DT had_VBD higher_JJR expressions_NNS
          than_IN did_VBD tumor_NN 9_CD of_IN the_DT progesterone_NN receptor_NN (_( 
          PR_NNP ;_: 2_CD ._. 7_CD -_: fold_VB )_) ,_, human_JJ mammaglobin_NN
          (_( 36_CD ._. 9_CD -_: fold_VB )_) ,_, and_CC the_DT human_JJ mammaglobin_NN β_NN precursor_NN
          (_( 29_CD ._. 1_LS -_: fold_VB )_) ,_, but_CC had_VBD lower_JJR expressions_NNS of_IN the_DT androgen_NN
          receptor_NN (_( 2_CD ._. 5_LS -_: fold_VB )_) ,_, 
          VEGF_NNP (_( 2_CD ._. 2_LS -_: fold_VB )_) ,_, 
          BARD-_NNP 1_CD (_( 3_CD ._. 5_LS -_: fold_VB )_) and_CC
          thrombospondin-_NN 1_CD (_( 2_CD ._. 2_LS -_: fold_VB )_) ._. These_DT findings_NNS suggest_VBP that_IN ,_,
          even_RB though_IN these_DT tumors_NNS appear_VBP similar_JJ in_IN stage_NN ,_, grade_NN
          and_CC ER_NNP status_NN ,_, they_PRP in_IN fact_NN exhibit_NN important_JJ differences_NNS
          in_IN gene_NN expression_NN that_WDT may_MD be_VB associated_VBN with_IN different_JJ
          clinical_JJ behaviors_NNS ._.
        
      
      
        Discussion_NNP
        Microarray_NNP technology_NN has_VBZ tremendous_JJ potential_NN in_IN cancer_NN
        research_NN and_CC diagnostics_NNS ._. The_DT genetic_JJ profiles_NNS of_IN tumors_NNS
        can_MD be_VB assessed_VBN and_CC compared_VBN in_IN a_DT global_JJ manner_NN ,_, thus_RB
        improving_VBG diagnosis_NN and_CC potentially_RB allowing_VBG
        individualization_NN of_IN treatment_NN strategies_NNS ._. Several_JJ studies_NNS
        [_NN 7_CD ,_, 8_CD ,_, 9_CD ]_NN have_VBP characterized_VBN the_DT gene_NN expression_NN patterns_NNS
        of_IN breast_NN cancers_NNS ,_, but_CC the_DT present_JJ study_NN is_VBZ the_DT first_JJ to_TO
        test_VB the_DT sensitivity_NN and_CC capabilities_NNS of_IN oligonucleotide_NN
        microarray_NN analysis_NN in_IN determining_VBG tumor_NN clonality_NN ._. The_DT
        expression_NN profiles_NNS of_IN adjacent_JJ breast_NN tumors_NNS from_IN one_CD
        individual_JJ ,_, and_CC of_IN tumors_NNS with_IN similar_JJ diagnostic_JJ
        characteristics_NNS (_( including_VBG grade_NN ,_, stage_NN ,_, and_CC hormone_NN
        status_NN )_) from_IN different_JJ individuals_NNS were_VBD compared_VBN ._.
        Additional_JJ experiments_NNS were_VBD preformed_JJ to_TO measure_VB
        chip-to-chip_JJ variation_NN and_CC variation_NN in_IN the_DT probe_NN
        preparation_NN process_NN ._. All_DT data_NNS sets_NNS were_VBD subjected_VBN to_TO both_DT
        pairwise_NN and_CC ranked_VBD correlation_NN calculations_NNS ._. These_DT
        analyses_NNS suggest_VBP that_IN complex_JJ data_NNS sets_NNS ,_, such_JJ as_IN those_DT
        derived_VBN from_IN microarray_NN experiments_NNS ,_, may_MD require_VB
        multiple-stage_JJ analysis_NN to_TO enhance_VB the_DT ability_NN to_TO detect_VB
        changes_NNS optimally_RB and_CC to_TO infer_NN biologic_JJ significance_NN from_IN
        expression_NN profiles_NNS ._.
        In_IN the_DT present_JJ study_NN ,_, a_DT 0_CD ._. 5_CD %_NN difference_NN was_VBD observed_VBN in_IN
        the_DT expression_NN profiles_NNS of_IN duplicate_VB experiments_NNS using_VBG the_DT
        Affymetrix_NNP U_NNP 95_CD A_DT chips_NNS ._. When_WRB the_DT total_JJ RNA_NNP was_VBD hybridized_JJ to_TO
        two_CD different_JJ U_NNP 95_CD A_DT chips_NNS ,_, the_DT data_NNS were_VBD found_VBN to_TO have_VB a_DT
        0_CD ._. 915_CD pairwise_NN correlation_NN ._. The_DT lower_JJR than_IN expected_VBN
        correlation_NN coefficient_NN ,_, which_WDT was_VBD related_VBN to_TO sample_NN
        preparation_NN variation_NN ,_, may_MD be_VB due_JJ to_TO a_DT small_JJ amount_NN of_IN RNA_NNP
        degradation_NN ._. Future_JJ experiments_NNS will_MD confirm_VB whether_IN this_DT
        variation_NN in_IN sample_NN preparation_NN is_VBZ predictable_JJ as_IN a_DT
        baseline_NN level_NN ._. The_DT 5_CD AsRNA_NNP expression_NN profile_NN differed_VBD from_IN
        that_DT of_IN 5_CD A_DT by_IN only_RB 165_CD genes_NNS ,_, which_WDT is_VBZ within_IN the_DT range_NN
        observed_VBD in_IN tumor_NN comparisons_NNS with_IN a_DT pairwise_NN correlation_NN
        coefficient_NN of_IN 0_CD ._. 987_CD -_: 0_CD ._. 980_CD ._. Additionally_RB ,_, when_WRB the_DT
        correlation_NN data_NN were_VBD further_JJ stratified_JJ by_IN rank_NN ,_, the_DT
        correlation_NN coefficients_NNS of_IN 5_CD A_DT and_CC 5_CD AsRNA_NNP more_RBR closely_RB
        resembled_JJ ranked_VBD correlations_NNS of_IN the_DT 5_CD A_DT and_CC 5_CD B_NNP experiments_NNS
        (_( Table_NNP 2_LS )_) ._. Regardless_RB ,_, a_DT small_JJ amount_NN of_IN chip-to-chip_JJ
        variation_NN and_CC sample_NN preparation_NN variation_NN is_VBZ to_TO be_VB
        expected_VBN when_WRB comparing_VBG microarray_NN experiments_NNS ._.
        The_DT number_NN of_IN genes_NNS that_WDT were_VBD differentially_RB expressed_VBN
        in_IN tumor_NN 5_CD A_DT as_IN compared_VBN with_IN tumor_NN 5_CD B_NNP (_( 149_CD -_: 182_CD genes_NNS )_)
        approximates_VBZ the_DT number_NN of_IN genes_NNS that_WDT are_VBP differentially_RB
        expressed_VBN as_IN a_DT result_NN of_IN variations_NNS in_IN sample_NN preparation_NN
        (_( 165_CD genes_NNS )_) ._. None_NN of_IN the_DT genes_NNS that_WDT were_VBD differentially_RB
        expressed_VBN between_IN these_DT adjacent_JJ tumors_NNS had_VBD a_DT known_VBN role_NN in_IN
        breast_NN cancer_NN development_NN ._. These_DT findings_NNS lead_VBP us_PRP to_TO
        conclude_VB that_IN tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP are_VBP essentially_RB
        indistinguishable_JJ by_IN microarray_NN analysis_NN ,_, suggesting_VBG that_IN
        they_PRP are_VBP likely_JJ to_TO be_VB derived_VBN from_IN the_DT same_JJ clone_NN ._.
        Interestingly_RB ,_, little_JJ heterogeneity_NN was_VBD detected_VBN between_IN
        tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP ,_, despite_IN the_DT fact_NN that_IN both_DT tumors_NNS had_VBD
        each_DT grown_VBN to_TO a_DT size_NN of_IN at_IN least_JJS 3_CD cm_NN ._.
        In_IN contrast_NN ,_, the_DT expression_NN profiles_NNS of_IN tumors_NNS 7_CD and_CC 9_CD
        showed_VBD marked_VBN differences_NNS from_IN that_DT of_IN tumor_NN 5_CD A_DT
        (_( correlation_NN coefficients_NNS of_IN 0_CD ._. 787_CD for_IN tumors_NNS 5_CD A_DT and_CC 7_CD ,_, and_CC
        0_CD ._. 745_CD for_IN tumors_NNS 5_CD A_DT and_CC 9_CD )_) ,_, with_IN the_DT expression_NN of_IN 1937_CD
        (_( tumors_NNS 5_CD A_DT and_CC 7_CD )_) and_CC 1764_CD (_( tumors_NNS 5_CD A_DT and_CC 9_CD )_) genes_NNS
        differing_VBG by_IN twofold_NN or_CC greater_JJR between_IN tumors_NNS ._. These_DT
        findings_NNS were_VBD confirmed_VBN in_IN a_DT larger_JJR sample_NN set_NN of_IN three_CD
        additional_JJ invasive_JJ tumors_NNS ,_, providing_VBG additional_JJ support_NN to_TO
        our_PRP$ findings_NNS ._. It_PRP is_VBZ interesting_JJ to_TO note_VB that_IN pairwise_NN
        comparisions_NNS of_IN tumor_NN 5_CD A_DT with_IN other_JJ invasive_JJ tumors_NNS had_VBD the_DT
        lowest_JJS correlations_NNS of_IN all_DT pairwise_NN comparisons_NNS ,_, indicating_VBG
        that_IN tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP may_MD be_VB phenotypically_RB distinct_JJ from_IN
        all_PDT the_DT other_JJ invasive_JJ tumors_NNS examined_VBD in_IN the_DT present_JJ
        study_NN ._.
        When_WRB the_DT gene_NN expression_NN profiles_NNS of_IN tumors_NNS 5_CD A_DT ,_, 5_CD B_NNP ,_, 7_CD ,_,
        and_CC 9_CD were_VBD compared_VBN ,_, a_DT difference_NN in_IN gene_NN expression_NN for_IN
        several_JJ genes_NNS that_WDT are_VBP known_VBN to_TO be_VB involved_VBN in_IN breast_NN
        cancer_NN was_VBD observed_VBN (_( Table_NNP 3_LS )_) ._. Most_JJS interestingly_RB ,_, the_DT
        expression_NN profiles_NNS of_IN the_DT tumors_NNS examined_VBD closely_RB reflect_VB
        the_DT hormone_NN receptor_NN status_NN ,_, as_IN measured_VBN clinically_RB ._. For_IN
        instance_NN ,_, tumor_NN 7_CD had_VBD a_DT lower_JJR level_NN of_IN ER_NNP transcript_NN than_IN
        did_VBD tumor_NN 5_CD A_DT ,_, which_WDT was_VBD paralleled_JJ by_IN a_DT decreased_VBN ER_NNP
        content_NN ._. Tumor_NNP 9_CD had_VBD the_DT highest_JJS PR_NNP gene_NN expression_NN ,_, as_RB
        well_RB as_IN the_DT highest_JJS PR_NNP content_NN ._. We_PRP were_VBD not_RB able_JJ to_TO detect_VB
        a_DT difference_NN in_IN expression_NN of_IN PR_NNP between_IN tumors_NNS 5_CD A_DT and_CC 7_CD ,_,
        however_RB ,_, despite_IN the_DT fact_NN that_DT tumor_NN 7_CD was_VBD PR_NNP positive_JJ (_( 150_CD
        fmol_NN /_NN mg_NN )_) and_CC 5_CD A_DT was_VBD PR_NNP negative_NN ,_, possibly_RB representing_VBG an_DT
        expression_NN difference_NN below_IN the_DT sensitivity_NN of_IN the_DT
        technology_NN (_( see_VB below_IN )_) ._. Lastly_NNP ,_, HER_NNP 2_CD was_VBD measured_VBN as_IN
        '_POS undetectable_JJ '_POS in_IN tumor_NN 9_CD at_IN diagnosis_NN ,_, but_CC was_VBD not_RB
        measured_VBN in_IN any_DT of_IN the_DT other_JJ tumors_NNS examined_VBD in_IN the_DT present_JJ
        study_NN ._. Therefore_RB ,_, the_DT lack_NN of_IN difference_NN in_IN expression_NN of_IN
        ERBB_NNP 2_CD detected_VBD in_IN each_DT of_IN these_DT tumors_NNS predicts_VBZ that_IN tumors_NNS
        5_CD A_DT ,_, 5_CD B_NNP ,_, and_CC 9_CD were_VBD also_RB Her-_NNP 2_CD receptor_NN negative_JJ ._.
        Since_IN the_DT initial_JJ draft_NN of_IN this_DT report_NN was_VBD prepared_VBN ,_, it_PRP
        was_VBD learned_VBN from_IN Affymetrix_NNP that_IN the_DT probe_NN set_VBD
        corresponding_JJ to_TO PR_NNP on_IN the_DT version_NN of_IN the_DT U_NNP 95_CD A_DT chip_NN used_VBN in_IN
        the_DT present_JJ study_NN was_VBD not_RB '_POS adequately_RB representative_NN '_'' of_IN
        the_DT human_JJ mRNA_NN and_CC promoter_NN region_NN DNA_NNP of_IN the_DT PR_NNP ,_, on_IN the_DT
        basis_NN of_IN recent_JJ changes_NNS to_TO the_DT annotations_NNS in_IN the_DT GenBank_NNP
        and_CC UniGene_NNP databases_NNS ._. These_DT findings_NNS may_MD present_VB an_DT
        explanation_NN as_IN to_TO why_WRB the_DT gene_NN expression_NN data_NNS for_IN the_DT PR_NNP
        in_IN this_DT study_NN did_VBD not_RB correlate_VBP with_IN the_DT protein_NN expression_NN
        measurements_NNS ._.
        Finally_RB ,_, transcripts_NNS from_IN several_JJ genes_NNS that_WDT are_VBP known_VBN
        to_TO play_VB a_DT role_NN in_IN breast_NN cancer_NN were_VBD not_RB detected_VBN in_IN any_DT of_IN
        the_DT tumors_NNS analyzed_VBD ,_, presumably_RB due_JJ to_TO low_JJ level_NN
        expression_NN ._. These_DT genes_NNS include_VBP :_: 
        BRCA_NNP 1_CD ,_, 
        EGFR_NNP ,_, 
        VEGF_NNP ,_, and_CC the_DT breast_NN cancer_NN
        suppressor_NN element_NN ,_, 
        CP_NNP 1_CD ._. Thus_RB ,_, there_EX is_VBZ an_DT important_JJ
        subset_NN of_IN genes_NNS that_WDT may_MD not_RB be_VB detected_VBN using_VBG this_DT
        technology_NN because_IN of_IN low_JJ transcript_NN levels_NNS ,_, or_CC that_DT may_MD
        not_RB be_VB regulated_VBN at_IN the_DT transcriptional_NN level_NN ._.
        In_IN conclusion_NN ,_, these_DT experiments_NNS demonstrate_VBP the_DT
        potential_NN for_IN oligonucleotide-based_JJ microarrays_NNS to_TO assess_VB
        tumor_NN clonality_NN and_CC tumor_NN heterogeneity_NN ._. Although_IN it_PRP is_VBZ
        currently_RB not_RB cost-effective_JJ to_TO array_NN every_DT tumor_NN sample_NN
        using_VBG an_DT Affymetrix_NNP chip_NN ,_, the_DT results_NNS of_IN these_DT experiments_NNS
        may_MD lead_VB to_TO identification_NN of_IN a_DT set_NN of_IN genetic_JJ markers_NNS that_WDT
        can_MD be_VB used_VBN to_TO generate_VB a_DT smaller_JJR diagnostic_JJ tumor_NN array_NN
        for_IN use_NN in_IN the_DT clinical_JJ setting_NN in_IN the_DT near_JJ future_NN ._.
      
      
        Abbreviations_NNP
        ER_NNP =_SYM estrogen_NN receptor_NN ;_: IDC_NNP =_SYM invasive_JJ ductal_NN carcinoma_NN ;_:
        PR_NNP =_SYM progesterone_NN receptor_NN ;_: VEGF_NNP =_SYM vascular_NN endothelial_NN
        growth_NN factor_NN ._.
      
      
        Supplementary_NNP material_NN
        
          Patients_NNS and_CC method_NN
          
            Study_NN subjects_NNS and_CC selection_NN criteria_NNS
            An_DT 87_CD year-old_JJ woman_NN underwent_VBD an_DT excisional_NN breast_NN
            biopsy_NN in_IN 1996_CD to_TO remove_VB two_CD tumor_NN masses_NNS at_IN the_DT 6_CD
            o'clock_RB and_CC 9_CD o'clock_RB positions_VBZ in_IN her_PRP$ right_JJ breast_NN
            (_( tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP ,_, respectively_RB )_) ._. Neither_DT mammography_NN ,_,
            intraoperative_JJ palpation_NN ,_, nor_CC histologic_JJ analysis_NN
            revealed_VBD a_DT physical_JJ connection_NN between_IN these_DT tumors_NNS ._. A_DT
            portion_NN of_IN the_DT tumor_NN was_VBD used_VBN for_IN clinical_JJ diagnostic_JJ
            purposes_NNS and_CC ,_, with_IN the_DT patient_NN 's_POS consent_NN ,_, the_DT remainder_NN
            of_IN the_DT tumor_NN was_VBD used_VBN for_IN research_NN purposes_NNS ._.
            Two_CD tumors_NNS from_IN separate_JJ consenting_VBG individuals_NNS were_VBD
            identified_VBN that_WDT had_VBD the_DT same_JJ stage_NN ,_, grade_NN ,_, and_CC ER_NNP
            characteristics_NNS as_IN tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP ,_, based_VBN on_IN the_DT
            pathology_NN reports_NNS (_( Table_NNP 1_LS )_) ._. The_DT tumors_NNS originated_VBN from_IN
            a_DT 36_CD year-old_JJ woman_NN who_WP underwent_VBD a_DT left_VBN breast_NN
            excisional_NN biopsy_NN in_IN 1997_CD (_( tumor_NN 7_CD )_) and_CC from_IN a_DT 76_CD
            year-old_JJ woman_NN who_WP underwent_VBD a_DT right_JJ excisional_NN breast_NN
            biopsy_NN in_IN 1998_CD (_( tumor_NN 9_CD )_) ._. The_DT three_CD additional_JJ invasive_JJ
            tumors_NNS added_VBD to_TO our_PRP$ data_NNS analysis_NN originated_VBN from_IN
            excisional_NN breast_NN biopsies_NNS from_IN a_DT 53_CD year-old_JJ woman_NN
            (_( tumor_NN 3_LS )_) ,_, a_DT 44_CD year-old_JJ woman_NN (_( tumor_NN 20_CD )_) and_CC a_DT 54_CD
            year-old_JJ woman_NN (_( tumor_NN 32_CD ;_: Supplementary_NNP Table_NNP 1_LS )_) ._. At_IN
            the_DT time_NN of_IN diagnosis_NN ,_, the_DT Her-_NNP 2_CD receptor_NN was_VBD measured_VBN
            as_IN 60_CD %_NN positive_JJ for_IN tumor_NN 3_CD and_CC found_VBD to_TO be_VB
            undetectable_JJ in_IN tumor_NN 9_CD ._. The_DT status_NN of_IN Her-_NNP 2_CD receptor_NN
            was_VBD not_RB measured_VBN for_IN any_DT of_IN the_DT other_JJ tumors_NNS used_VBN in_IN
            the_DT present_JJ study_NN ._.
          
          
            Tumor_NNP handling_VBG
            After_IN the_DT gross_JJ pathologic_JJ diagnosis_NN was_VBD completed_VBN ,_,
            the_DT remaining_VBG portion_NN of_IN each_DT tumor_NN used_VBN in_IN the_DT present_JJ
            study_NN was_VBD snap_NN frozen_VBN in_IN liquid_JJ nitrogen_NN and_CC placed_VBN in_IN
            a_DT freezer_NN at_IN -_: 80_CD °_NN C_NNP until_IN use_NN ._.
          
          
            Tumor_NNP analysis_NN
            In_IN order_NN to_TO confirm_VB the_DT clinical_JJ diagnosis_NN and_CC to_TO
            identify_VB regions_NNS of_IN the_DT tumor_NN specimen_NN that_WDT contained_VBD
            90_CD %_NN or_CC greater_JJR IDC_NNP ,_, frozen_VBN sections_NNS were_VBD prepared_VBN from_IN
            each_DT of_IN the_DT tumors_NNS ._. The_DT side_NN of_IN the_DT tumor_NN with_IN the_DT
            greatest_JJS surface_NN area_NN was_VBD designated_VBN the_NNP '_POS front_NN '_'' of_IN the_DT
            tumor_NN ,_, and_CC the_DT opposing_VBG side_NN was_VBD designated_VBN the_NNP '_POS back_RB '_'' ._.
            A_DT frozen_VBN section_NN was_VBD made_VBN of_IN the_DT front_NN and_CC back_RB of_IN each_DT
            of_IN the_DT tumor_NN ,_, and_CC the_DT sections_NNS were_VBD stained_JJ with_IN
            hema-toxylin_JJ and_CC eosin_NN to_TO visualize_VB the_DT tumor_NN and_CC to_TO
            verify_VB that_IN the_DT cell_NN population_NN content_NN was_VBD consistent_JJ
            throughout_IN the_DT tumor_NN ._.
          
        
      
      
        Results_NNS
        
          Analysis_NNP and_CC confirmation_NN of_IN tumor_NN
          characteristics_NNS
          Frozen_NNP sections_NNS stained_JJ with_IN hematoxylin_NN and_CC eosin_NN of_IN
          tumors_NNS 5_CD A_DT and_CC 5_CD B_NNP contained_VBD a_DT 90_CD %_NN or_CC greater_JJR IDC_NNP
          population_NN ,_, as_IN determined_VBN by_IN a_DT surgical_JJ pathologist_NN (_( MR_NNP )_) ,_,
          and_CC thus_RB did_VBD not_RB require_VB further_JJ dissection_NN ._. Tumors_NNP 3_CD ,_, 7_CD ,_,
          9_CD ,_, 20_CD ,_, and_CC 32_CD were_VBD found_VBN to_TO contain_VB small_JJ adjacent_JJ ductal_NN
          carcinoma_NN 
          in_IN situ_NN components_NNS ,_, which_WDT were_VBD
          macrodissected_JJ from_IN the_DT IDC_NNP portion_NN of_IN the_DT tumors_NNS ._. In_IN
          order_NN to_TO confirm_VB that_IN the_DT ductal_NN carcinoma_NN 
          in_IN situ_NN cells_NNS were_VBD completely_RB
          removed_VBN from_IN the_DT samples_NNS ,_, the_DT dissected_VBN tumors_NNS were_VBD
          resectioned_JJ and_CC stained_JJ ._. The_DT frozen_VBN sections_NNS taken_VBN of_IN the_NNP
          '_POS front_NN '_'' (_( see_VB Supplementary_NNP material_NN ,_, Tumour_NNP analysis_NN )_) of_IN
          tumors_NNS 5_CD A_DT ,_, 5_CD B_NNP ,_, 7_CD ,_, and_CC 9_CD may_MD be_VB seen_VBN in_IN Supplementary_NNP Fig_NNP ._.
          1_LS ._.
        
      
    
  
